A team of American and British scientists have discovered genetic connections between sleep disturbance and a range of medical disorders including obesity.
Lead author Jacqueline Lane, PhD, postdoctoral fellow at Massachusetts General Hospital (MGH), and joint senior authors Richa Saxena, PhD, assistant professor of Anæsthesia at MGH and Harvard Medical School, and Martin K Rutter, MD, FRCP, senior lecturer in Cardiometabolic Medicine from The University of Manchester, published their groundbreaking research in Nature Genetics.
The study looked at the biological controllers of sleep duration, insomnia, and excessive daytime sleepiness and how they linked to the health and life histories of more than 112,000 people taking part in the world-leading UK Biobank study. Study participants reported their sleep duration, the degree of insomnia and daytime sleepiness, and then had their genes mapped. Other information about them, such as their weight and any diseases they suffered from, was also collected.
The researchers identified for the first time areas of the genome that are associated with sleep disturbance—including insomnia and excessive daytime sleepiness—and also discovered novel genetic links with several medical conditions, including restless legs syndrome, schizophrenia, and obesity. The strongest genetic association for insomnia symptoms fell within a gene previously linked to restless legs syndrome. Other gene regions were important for insomnia, but selectively in either men or women.
The team also identified genetic links between longer sleep duration and schizophrenia risk and between increased levels of excessive daytime sleepiness and measures of obesity (body mass index and waist circumference). The research also suggested that insomnia has shared underlying biology with major depression and abnormal glucose metabolism.
Funded by the U.S. National Institutes of Health and The University of Manchester’s Research Innovation Fund, the study marks a major advance in understanding the biology of sleep.
Rutter says in a release, “This clinical science is an important step forwards in understanding the biological basis for these conditions; so it’s very exciting. Scientists have long observed a connection between sleep disorders and these conditions in epidemiological studies. But this is the first time these biological links have been identified at a molecular level.”
UK Biobank aims to improving the prevention, diagnosis, and treatment of a wide range of serious and life-threatening illnesses. Lane says, “We’re particularly pleased to be able to use UK Biobank data in this way; it’s an amazing resource for scientists.”
Saxena adds, “It’s important to remember there is no molecular targeting available for conditions which affect sleep: all we really have are sedatives. So we hope that this research will enable scientists to develop new ways to intervene on a range of conditions in a much more fundamental way. We acknowledge these findings will need further study, but we believe this knowledge amounts to a key advance in our understanding of the biology behind sleep—a major influence on our health and behavior.”